BioSpace News Archive

Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced the pricing of its previously announced underwritten public offering of 3,571,428 shares of its common stock at a public offering price of $70.00 per share.

Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that Anthony Galdi has been named the Chief Commercial Officer of the Innocoll Group of Companies, effective mid-February. Galdi succeeds Jim Helm, who is retiring and has agreed to assist with the leadership transition. This press release features multimedia. View the full release here: https

Bristol Myers Squibb Reports Fourth Quarter Revenues of $11.1 Billion; Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and Non-GAAP EPS of $1.46; Full-Year Loss Per Share of $3.99 and Non-GAAP EPS of $6.44 Completes Acquisition of MyoKardia, Expanding Leading Cardiovascular Franchise

Neutra Corp. (OTC PINK: NTRR ) has decided to release a statement that management does not plan on having a share consolidation, also known as a reverse split at this time. Instead, the Company will focus on the growth of its wholly owned subsidiary VIVIS CBD.

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, and NeoGenomics, Inc.(NASDAQ:NEO), a leading provider of cancer-focused genetic testing services announced a strategic partnership

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as Cushing’s disease and congenital adrenal hyperplasia (CAH)

CytoSorbents Corporation (NASDAQ: CTSO), highlights the recent release from the United Kingdom’s internationally renowned National Institute for Health and Care Excellence (NICE) of a Medtech Innovation Briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery.

McKesson, a global leader in healthcare committed to transforming cancer research, has joined together with life sciences companies, oncology providers and patient advocacy groups in a unique collaborative effort, titled MYLUNG, to advance precision medicine options for non-small cell lung cancer (NSCLC) patients who are being treated in the community.

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced completion of enrollment in the pivotal Phase 2 clinical trial evaluating camidanlumab tesirine

Baxter Reports Fourth-quarter sales of $3.2 billion increased 5% on a reported basis, 3% on a constant currency basis and 2% on an operational basis 1 Fourth-quarter U.S. GAAP earnings per share (EPS) were $0.33 and adjusted EPS were $0.80 Full-year revenue of $11.7 billion increased 3% on both a reported and constant currency basis and 2% on an operational basis